CE-marked antibody tests expand EUROIMMUN’s comprehensive portfolio of laboratory products to support the analysis of the immune response to COVID-19
Waltham, MASS. – June 13, 2022 – EUROIMMUN, a PerkinElmer, Inc. company, today announced the launch of two CE marked assays – the Anti-SARS-CoV-2 RBD ChLIA (IgG) and the Anti-SARS-CoV-2 Omicron ELISA (IgG). Both test systems enable the detection of IgG antibodies formed against SARS-CoV-2 and are available to laboratories in countries that accept the CE mark.
Research shows that immune responses to SARS-Cov-2 infection, which are often measured by neutralizing antibody titers, can vary greatly among people. Understanding how antibody levels decrease over time in certain individuals and populations could help answer critical epidemiological, clinical and virological questions, including those that lead to limiting virus transmission and further developing COVID-19 vaccines and therapeutics.
The Anti-SARS-CoV-2 RBD ChLIA (IgG) enables the quantitative measurement of IgG antibodies formed against the receptor binding domain (RBD) of SARS-CoV-2. In doing so, it offers the possibility to convert the determined antibody concentration into standardized units (BAU/ml). This assay is suitable for the determination of IgG antibody responses both after infection or vaccination with a spike protein-based vaccine. EUROIMMUN also offers the IDS-i10 and IDS-iSYS Multi-Discipline Automated System that allow for automated processing of chemiluminescence immunoassays such as this one.
“There is currently no uniform serological correlate that helps determine whether or not a person’s immune system is able to effectively defend against SARS-CoV-2,” explained Dr. Wolfgang Schlumberger, CEO of EUROIMMUN. “This is why further research into humoral immunity and the body’s response to pathogens like SARS-CoV-2 remains important and gives us a reason to continue innovating and developing assays to enable discoveries in this area.”
Similarly, the Anti-SARS-CoV-2 Omicron ELISA (IgG) further complements EUROMMUN’s portfolio of SARS-CoV-2 offerings. With Omicron remaining the dominant SARS-CoV-2 variant in many countries worldwide, this assay is based on the recombinant S1 subunit of the spike protein of the SARS-CoV-2 Omicron variant and can be used to quantify IgG antibodies formed against the virus.
The EUROIMMUN COVID-19 diagnostics portfolio also includes two real-time PCR tests, an antigen ELISA for acute diagnostics, as well as several serological tests for differentiated detection of antibodies (IgA, IgM, IgG) against SARS-CoV-2 antigens. Furthermore, EUROIMMUN offers an Interferon-gamma Release Assay (IGRA) to determine the activity of SARS-CoV-2-reactive T cells.
To learn more about all of these and related offerings, visit www.coronavirus-diagnostics.com/.
About PerkinElmer
PerkinElmer is a leading, global provider of end-to-end solutions that help scientists, researchers and clinicians better diagnose disease, discover new and more personalized drugs, monitor the safety and quality of our food, and drive environmental and applied analysis excellence. With an 85-year legacy of advancing science and a mission of innovating for a healthier world, our dedicated team of more than 16,000 collaborates closely with commercial, government, academic and healthcare customers to deliver reagents, assays, instruments, automation, informatics and strategic services that accelerate workflows, deliver actionable insights and support improved decision making. We are also deeply committed to good corporate citizenship through our dynamic ESG and sustainability programs. The Company reported revenues of approximately $5 billion in 2021, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available at www.perkinelmer.com. Follow PerkinElmer on LinkedIn, Twitter, Facebook, Instagram, and YouTube.
Media Relations:
Chet Murray
(781) 663-5719
chet.murray@perkinelmer.com